0001213900-24-035721.txt : 20240424 0001213900-24-035721.hdr.sgml : 20240424 20240424140804 ACCESSION NUMBER: 0001213900-24-035721 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240419 FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lowdell Mark William CENTRAL INDEX KEY: 0001767037 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38793 FILM NUMBER: 24869601 MAIL ADDRESS: STREET 1: THE OAK, WLX ROAD CITY: BEAUMONT STATE: X0 ZIP: CO16 0AT ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inmune Bio, Inc. CENTRAL INDEX KEY: 0001711754 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475205835 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 BUSINESS PHONE: 8589643720 MAIL ADDRESS: STREET 1: 225 NE MIZNER BLVD, SUITE 640 CITY: BOCA RATON STATE: FL ZIP: 33432 4/A 1 ownership.xml X0508 4/A 2024-04-19 2024-04-23 0 0001711754 Inmune Bio, Inc. INMB 0001767037 Lowdell Mark William C/O INMUNE BIO INC. 225 NE MIZNER BLVD., SUITE 640 BOCA RATON FL 33432 0 1 1 0 Chief Scientific Officer 0 Common Stock 2024-04-19 4 P 0 14423 8.32 A 1510806 D Common Stock Warrants (right to buy) 9.152 2024-04-19 4 P 0 14423 0.125 A 2024-04-24 Common Stock 14423 14423 D The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $121,802.24 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. The original Form 4, filed on April 23, 2024 is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the transaction as an award in column 3 of Table I and column 4 of table II instead of a purchase. The reporting person purchased the securities in a registered direct transaction from the Company. /s/ Mark William Lowdell 2024-04-24